Chronic toxicity of anthracyclines occurs weeks or months after administration.
Instead of continuing each chemotherapy side effect listed on the package inserts we have compiled a list of every side effect on this page so far.
List of Side Effects listed from this Article Alone
Hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia
A faster heartbeat than a usual heartbeat.
Abnormal bleeding or bruising
Abnormalities of the heart seen on electrocardiograms
Acute uric acid nephropathy
Adverse cardiovascular effects reported in 1-10% of patients receiving pegylated liposomal doxorubicin for ovarian cancer include vasodilation, tachycardia, deep thrombophlebitis, hypotension, pallor, and cardiac arrest.
Amyloidosis can affect your kidneys, heart, liver, intestines, and nerves.
An enlarged heart (cardiomegaly)
Anaphylactic reactions have been reported; death has also been reported in association with this event.
As nitrogen mustard therapy may contribute to Amyloidosis; a serious health problem that can lead to life-threatening organ failure. Amyloidosis frequently involves the heart and kidneys. It is a rare disease but it is induced by this drug as a side effect. It is an extremely serious condition caused by this toxic chemotherapy drug.
Ataxia – May become permanent – slurred speech, stumbling, falling, and incoordination. All are related to degeneration of the part of the brain responsible for coordination, called the cerebellum.
Black, tarry stools
Bleeding from the gums or nose, blood in bowel movements or urine, or heavy bleeding from a cut
Bleeding problems including:
Bone marrow depression
Bone, limb and back pain
BOXED WARNING/ WARNING: CARDIOMYOPATHY. Myocardial damage, including acute left ventricular failure can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20%
BOXED WARNING/ WARNING: SEVERE MYELOSUPPRESSION. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.
Can cause hypereosinophilic syndrome – damage to the heart leading to cardiac failure. Causes shortness of breath and swollen ankles; can cause the development of rashes on the skin. Can also cause enlargement of the spleen and liver.
Caregivers of children receiving doxorubicin should be advised to take precautions (e.g., wearing latex gloves) to prevent contact with the patient’s urine and other body fluids for at least five days after administration of doxorubicin.
Chronic cardiotoxicity, such as congestive heart failure or cardiomyopathy, usually occurs within 1 year after discontinuance of anthracycline therapy, is more common than acute cardiotoxicity, and is considered clinically the most important anthracycline-associated toxicity. Tachycardia, tachypnea, dilation of the heart, exercise intolerance, pulmonary and venous congestion, poor perfusion, and pleural effusion; these manifestations may respond to cardiac supportive therapy and may be self-limiting, or, alternatively, may be irreversible and unresponsive to therapy and fatal. In one retrospective review, congestive heart failure developed in 3, 7, or 21% of patients
Colicky abdominal pain
Combination antineoplastic regimens can cause sinusoidal obstruction syndrome, but the role of doxorubicin, epirubicin and idarubicin in this outcome is often not clear.
Congenital malformation in the fetus
Congestive heart failure is the most common cardiac complication of amyloidosis.
Cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts
Cyclophosphamide has been shown to increase the risk of secondary malignancies such as leukemia and urothelial cell carcinoma
Depression of the achilles tendon reflex
Diplopia and corneal hypesthesia
Dizziness or trouble thinking clearly
Fatigue and loss of energy
Feeling tired and weak
Feeling tired, weak, dizzy, or short of breath
Fever higher than 100.5˚F (38˚C)
Frequent fevers or infections
Gastrointestinal upset and leucopenia
Generalized sensorimotor dysfunction
Hemorrhagic cystitis may develop in patients treated with Cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis.
Hypoplasia of all elements of bone marrow
Impaired spermatogenesis, azoospermia, and total germinal aplasia. (Infertility may be reversed several years after stopping drug)
In a few instances with high doses of Cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first Cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis.
Inappropriate antidiuretic hormone (ADH) secretion
Intestinal necrosis and/or perforation
Irregular heartbeat (arrhythmias)
Ischemic cardiac toxicity and syndrome of hyponatremia
It may cause sterility in both sexes.
Laryngeal nerve paralysis causing hoarseness or cough
Late-onset anthracycline-induced cardiotoxicity, which may be life-threatening, occurs several years or even decades after discontinuance of anthracycline therapy and it may develop after a prolonged asymptomatic interval.
Leukopenia occurs in patients treated with Cyclophosphamide
Loss of deep tendon reflexes
Maculopapular skin eruption
More urination than usual, or the need to urinate right away
Mustargen has been reported to have immunosuppressive activity. It may predispose the patient to bacterial, viral or fungal infection. It destroys your bodies natural ability to fight off cancer.
Mustargen may be associated with an increased incidence of a second malignant tumor. The cancer drug causes cancer.
Nausea/vomiting (may be severe)
Neuritic pain and motor difficulties
Neuromuscular and neurological disturbances
Numbness and tingling of the fingers and toes
Ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement)
Oligomenorrhea – Infrequent menstrual periods
Optic atrophy and blindness
Ovarian fibrosis with apparently complete loss of germ cells after prolonged Cyclophosphamide treatment in late prepubescence has been reported.
Pain or bruising on your lower back or sides
Pain when you urinate
Pale or yellow skin
Pale skin or purple or red dots on the skin
Paralytic ileus, abdominal cramps
Paresthesias in the fingers and toes
Parotid gland pain
Pericarditis has been reported independent of any hemopericardium.
Peripheral neuropathy with paresthesia (pricking, chilling, burning, or numb sensation) of the extremities and depressed deep tendon reflexes were reported to occur in 17% of patients. May become permanent
Permanent central nervous system damage
Persistent pancytopenia (low counts for all three types of blood cells: red blood cells, white blood cells, and platelets.) have been reported.
Petechiae – When capillaries bleed, leaking blood into the skin.
Pinpoint red spots on the skin
Purpura -also called blood spots or skin hemorrhages epistaxis
Rarely, hemolytic anemia associated with such diseases as the lymphomas and chronic lymphocytic leukemia may be precipitated by treatment with alkylating agents including Mustargen. This drug causes cancer
Rash, oral ulceration
Redness, swelling, or pain at the injection site
Renal or adrenal disease
Ringing in the ears or decreased ability to hear
Second malignancies have developed in some patients treated with Cyclophosphamide
SECONDARY MALIGNANCIES. Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride
Seizures and coma have been reported in patients receiving doxorubicin in combination with cisplatin or vincristine.
Severe thrombocytopenia may lead to bleeding from the gums and gastrointestinal tract, petechiae, and small subcutaneous hemorrhages.
Shortness of breath
Shortness of breath upon exertion
Sores in the mouth and on the lips
Spinning sensation or dizziness (vertigo)
Spitting of blood that originated in the lungs or bronchial tubes.
Sudden shortness of breath
Swelling of the feet or lower legs
Temporary hair loss
Temporary or permanent amenorrhea. – No menstrual periods
The use of conventional or liposomal doxorubicin may cause cardiac toxicity.
The use of doxorubicin (Chemo drug) or other topoisomerase II inhibitors in children is associated with increased risk of acute myelogenous leukemia and other secondary malignancies.
Thrombocytopenia (A lower platelet count can cause bleeding problems) have been reported to occur frequently.
Tightness of the chest and throat
Tightness of the chest and throat
Tightness of the chest and throat
Tingling and numbness of the extremities
Ulceration and necrosis of the colon, particularly the cecum, leading to bleeding or severe and possibly fatal infection, have occurred in patients with acute myelogenous leukemia who received combined doxorubicin and cytarabine therapy.
Unusual tiredness or weakness
Unusually rapid heart beat
Urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves
Yellow eyes or skin